HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$36.57
Day range
$35.21 - $36.76
Year range
$23.15 - $39.33
Market cap
1.80B USD
Avg Volume
312.82K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2025info | Y/Y change |
---|---|---|
Revenue | 97.96M | 29.93% |
Operating expense | 42.79M | 10.75% |
Net income | -10.30M | 11.33% |
Net profit margin | -10.51 | 31.80% |
Earnings per share | -0.20 | 13.04% |
EBITDA | -14.10M | 6.19% |
Effective tax rate | -6.25% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 882.81M | 2.70% |
Total assets | 1.08B | 5.77% |
Total liabilities | 693.91M | 4.47% |
Total equity | 388.48M | — |
Shares outstanding | 50.39M | — |
Price to book | 4.74 | — |
Return on assets | -3.52% | — |
Return on capital | -4.54% | — |
Cash Flow
Net change in cash
(USD) | Jun 2025info | Y/Y change |
---|---|---|
Net income | -10.30M | 11.33% |
Cash from operations | 25.96M | 10.62% |
Cash from investing | -30.41M | 91.32% |
Cash from financing | 3.67M | 548.66% |
Net change in cash | 11.09M | 103.38% |
Free cash flow | 12.10M | -48.73% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
493